FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4246813212> ?p ?o ?g. }

• W4246813212 endingPage "e15030" @default.
• W4246813212 startingPage "e15030" @default.
• W4246813212 abstract "e15030 Background: Management of advanced prostate cancer with relapse after initial hormonal therapy is still challenging. Some reports have shown that the second line maximum androgen blockade with an alternative antiandrogen (2nd MAB) is still effective. However 2nd MAB has relatively low PSA response rate of about 35%. We sought to determine whether the combination therapy of 2nd MAB and UFT would be even more effective than 2nd MAB alone and also to correlate the treatment effect with the thymidylate synthase (TS) mRNA expression levels. Methods: Patients who were histologically confirmed with prostate cancer and relapsed after LH-RH analogue alone or MAB were included in this study. ECOG performance status was 0-2. All patients were randomly allocated into two groups, 2nd MAB (group A) or 2nd MAB combined with UFT orally at a dose of 260 mg/m2/day (group B) until recurrence. The primary endpoint was PSA response rate (effectiveness defined as > 50% decrease of PSA) and one of the secondary endpoint was PFS. TS mRNA expression levels in formalin fixed paraffin embedded biopsy specimens were measured by RT-PCR method. Results: Fifty three patients were enrolled in this study and clinical data for 38 patients were available so far. Median age was 76 (47-89) years. There were no severe AEs in both groups. PSA response rate in group B (70.6%) tended to be higher than that in group A (36.8%) (p=0.0543). Group B (16.1 months) had significantly longer median PFS than group A (6.4 months) (p=0.0028). Biopsy samples were available in 33 patients for TS mRNA measurement. Interestingly, among patients who were treated with 2nd MAB combined with UFT, those with low TS (88%) had higher PSA response rate than those with high TS (57%). Conclusions: After relapse with initial hormonal therapy, 2nd MAB along with UFT is an effective and well-tolerated treatment option before introducing docetaxel, especially for elderly patients with prostate cancer with low TS expression level. No significant financial relationships to disclose." @default.
• W4246813212 created "2022-05-12" @default.
• W4246813212 creator A5000268146 @default.
• W4246813212 creator A5002564503 @default.
• W4246813212 creator A5014728775 @default.
• W4246813212 creator A5021893341 @default.
• W4246813212 creator A5025356597 @default.
• W4246813212 creator A5056792289 @default.
• W4246813212 creator A5063657513 @default.
• W4246813212 creator A5071103362 @default.
• W4246813212 creator A5072201711 @default.
• W4246813212 creator A5075350059 @default.
• W4246813212 date "2010-05-20" @default.
• W4246813212 modified "2023-10-18" @default.
• W4246813212 title "A multicenter, randomized phase II study of second-line maximum androgen blockade with an alternative antiandrogen combined with tegafur-uracil (UFT) for prostate cancer with relapse after initial hormonal therapy." @default.
• W4246813212 doi "https://doi.org/10.1200/jco.2010.28.15_suppl.e15030" @default.
• W4246813212 hasPublicationYear "2010" @default.
• W4246813212 type Work @default.
• W4246813212 citedByCount "0" @default.
• W4246813212 crossrefType "journal-article" @default.
• W4246813212 hasAuthorship W4246813212A5000268146 @default.
• W4246813212 hasAuthorship W4246813212A5002564503 @default.
• W4246813212 hasAuthorship W4246813212A5014728775 @default.
• W4246813212 hasAuthorship W4246813212A5021893341 @default.
• W4246813212 hasAuthorship W4246813212A5025356597 @default.
• W4246813212 hasAuthorship W4246813212A5056792289 @default.
• W4246813212 hasAuthorship W4246813212A5063657513 @default.
• W4246813212 hasAuthorship W4246813212A5071103362 @default.
• W4246813212 hasAuthorship W4246813212A5072201711 @default.
• W4246813212 hasAuthorship W4246813212A5075350059 @default.
• W4246813212 hasConcept C121608353 @default.
• W4246813212 hasConcept C126322002 @default.
• W4246813212 hasConcept C126894567 @default.
• W4246813212 hasConcept C143998085 @default.
• W4246813212 hasConcept C168563851 @default.
• W4246813212 hasConcept C203092338 @default.
• W4246813212 hasConcept C2776235491 @default.
• W4246813212 hasConcept C2777299880 @default.
• W4246813212 hasConcept C2778311097 @default.
• W4246813212 hasConcept C2778313021 @default.
• W4246813212 hasConcept C2779322244 @default.
• W4246813212 hasConcept C2780192828 @default.
• W4246813212 hasConcept C2780962315 @default.
• W4246813212 hasConcept C61367390 @default.
• W4246813212 hasConcept C71924100 @default.
• W4246813212 hasConcept C90924648 @default.
• W4246813212 hasConceptScore W4246813212C121608353 @default.
• W4246813212 hasConceptScore W4246813212C126322002 @default.
• W4246813212 hasConceptScore W4246813212C126894567 @default.
• W4246813212 hasConceptScore W4246813212C143998085 @default.
• W4246813212 hasConceptScore W4246813212C168563851 @default.
• W4246813212 hasConceptScore W4246813212C203092338 @default.
• W4246813212 hasConceptScore W4246813212C2776235491 @default.
• W4246813212 hasConceptScore W4246813212C2777299880 @default.
• W4246813212 hasConceptScore W4246813212C2778311097 @default.
• W4246813212 hasConceptScore W4246813212C2778313021 @default.
• W4246813212 hasConceptScore W4246813212C2779322244 @default.
• W4246813212 hasConceptScore W4246813212C2780192828 @default.
• W4246813212 hasConceptScore W4246813212C2780962315 @default.
• W4246813212 hasConceptScore W4246813212C61367390 @default.
• W4246813212 hasConceptScore W4246813212C71924100 @default.
• W4246813212 hasConceptScore W4246813212C90924648 @default.
• W4246813212 hasIssue "15_suppl" @default.
• W4246813212 hasLocation W42468132121 @default.
• W4246813212 hasOpenAccess W4246813212 @default.
• W4246813212 hasPrimaryLocation W42468132121 @default.
• W4246813212 hasRelatedWork W1989858958 @default.
• W4246813212 hasRelatedWork W2026851921 @default.
• W4246813212 hasRelatedWork W2046708270 @default.
• W4246813212 hasRelatedWork W2087208265 @default.
• W4246813212 hasRelatedWork W2093549003 @default.
• W4246813212 hasRelatedWork W2127440557 @default.
• W4246813212 hasRelatedWork W2946522155 @default.
• W4246813212 hasRelatedWork W36066310 @default.
• W4246813212 hasRelatedWork W4246813212 @default.
• W4246813212 hasRelatedWork W83392053 @default.
• W4246813212 hasVolume "28" @default.
• W4246813212 isParatext "false" @default.
• W4246813212 isRetracted "false" @default.
• W4246813212 workType "article" @default.